Open Accessibility Menu

Antibody Infusion

Antibody infusion is ONLY recommended for high risk COVID-19 positive, non-hospitalized patients.

The antibody infusion (Bamlanivimab/Regeneron) has been emergently approved by the FDA for the treatment of mild to moderate COVID-19 in non-hospitalized patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 88 lbs. and who are at high risk for progressing to severe COVID-19 and/or hospitalization. High risk is defined as non-hospitalized patients who meet at least one of the following criteria:

  • Have a body mass index (BMI) ≥35
  • Have chronic kidney disease
  • Have diabetes
  • Have immunosuppressive disease
  • Are currently receiving immunosuppressive treatment
  • Are ≥65 years of age
  • Are 55 years or older with cardiovascular disease, HTN or COPD/other respiratory disease

Bamlanivimab is a neutralizing antibody drug. When there's a virus in your body, like COVID-19, your immune system makes antibodies to fight it off. But it takes time for your body to make antibodies for a new virus- and in the meantime, you could get very sick.

Bamlanivimab contains man-made antibodies that are similar to the antibodies of patients who recovered from COVID-19. Scientists think that these antibodies may help limit the amount of virus in your body. This could give your body more time to learn how to make its own antibodies. Bamlanivimab does not have any COVID-19 virus in it.

In a clinical trial, scientists found that bamlanivimab may limit the amount of virus in the body for people with COVID-19 who take the drug within 10 days of symptoms starting. They may also be less likely to require hospitalization.

Outpatient Antibody Infusion is provided at Anderson Regional Medical Center- South. Ask your doctor if you are a candidate for this treatment.